Codi QR

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

BRAF inhibitor-resistant melanomas (BRAFiR) acquire (epi)genetic and functional alterations that enable them to evade alternative treatments. Identifying these alterations is critical to advancing treatment strategies. Here, we explored the effect of Chk1 inhibition (Chk1i) on BRAFiR cells, revealin...

Descripció completa

Guardat en:
Autors principals: Danielle G. Carvalho, Juliana C.N. Kenski, Daniel A. Moreira, Matheus A. Rajão, Oscar Krijgsman, Carolina Furtado, Mariana Boroni, João P.B. Viola, Daniel S. Peeper, Patricia A. Possik
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2025-07-01
Col·lecció:Pharmacological Research
Matèries:
Melanoma
BRAF
Targeted therapy
Replication Stress
Accés en línia:http://www.sciencedirect.com/science/article/pii/S1043661825002221
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars